Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,843 across all filing types
Latest filing 2014-11-24 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
拟收购浙江普洛得邦医药销售有限公司49%股权项目资产评估报告书
Audit Report / Information Classification · 95% confidence The document is titled as an "资产评估报告书" which translates to "Asset Evaluation Report" or "Asset Appraisal Report." It is a detailed report prepared by an appraisal company (Beijing China Alliance Appraisal Co., Ltd.) for Pu Luo Pharmaceutical Co., Ltd. regarding the acquisition of 49% equity in Zhejiang Pu Luo De Bang Pharmaceutical Sales Co., Ltd. The report includes detailed valuation methods, asset and liability breakdowns, legal and regulatory references, and a comprehensive explanation of the appraisal process and conclusions. It is not a general annual or quarterly financial report, nor is it an announcement or a brief summary. It is a standalone detailed audit and valuation report related to a specific transaction (equity acquisition). This fits the category of an Audit Report / Information (AR) as it contains the results of an asset valuation and related audit information, but is not a full annual report or earnings release. The document length (15,000 characters) and content confirm it is the full report, not just an announcement or certification. Therefore, the appropriate classification is AR with high confidence.
2014-11-24 Chinese
第六届董事会第七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a board meeting resolution by 普洛药业股份有限公司 (Puluo Pharmaceutical Co., Ltd.). It includes details about the meeting date, method, and the voting result on a specific agenda item regarding acquisition of partial equity in another company. There is no financial data, no report attached or referenced as published, and no indication of a full report or regulatory filing. The content is focused on board decisions and resolutions, which fits the category of Board/Management Information (MANG). The document length is short and it is not a report publication announcement or certification. Therefore, the classification is MANG with high confidence.
2014-11-24 Chinese
关于2014年新增关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a new related party transaction in 2014 by 普洛药业股份有限公司. It details the transaction overview, parties involved, contract terms, pricing policy, and independent director opinions. It is a regulatory announcement about a specific transaction rather than a financial report, earnings release, or management discussion. The document length is 2587 characters, which is relatively short and focused on a single transaction disclosure. This fits the profile of a Regulatory Filing (RNS) as it is a compliance disclosure about related party transactions and does not contain comprehensive financial statements or management analysis. Therefore, the appropriate classification is Regulatory Filings (RNS).
2014-11-20 Chinese
第六届董事会第六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a board meeting resolution by 普洛药业股份有限公司 (Puloyao Pharmaceutical Co., Ltd.). It includes details about the meeting date, method, compliance with company law, and voting results on a specific agenda item regarding related party transactions. There is no financial data, no mention of annual or quarterly reports, no audit information, and no investor presentation. The document is clearly a Board/Management Information announcement about board decisions and resolutions. The document length is short and focused on board meeting resolutions, fitting the Board/Management Information (MANG) category.
2014-11-20 Chinese
2014年第三季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled "普洛药业股份有限公司 2014 年第三季度报告全文" which translates to "Puluo Pharmaceutical Co., Ltd. 2014 Third Quarter Report Full Text." It contains detailed financial data including consolidated and parent company balance sheets, profit and loss statements, cash flow information, shareholder data, and management's discussion of financial performance for the third quarter of 2014. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year (quarterly) clearly indicates this is an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains actual financial data rather than just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2014
2014-10-28 Chinese
2014年第三季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2014 Third Quarter Report" of 普洛药业股份有限公司, indicating it is a quarterly financial report. It contains detailed financial data such as total assets, net profit, earnings per share, cash flow, and shareholder information for the third quarter of 2014. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year confirms it is an Interim / Quarterly Report. The document length (8178 characters) and content confirm it is the report itself, not just an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q3 2014
2014-10-28 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.